Category Archives: Corporate

One of the impediments to a reasonable public dialogue regarding the creation of a pathway for the approval of biosimilars has been the deluge of misinformation.  It is difficult to choose where to begin in correcting the numerous falsehoods in a recent guest editorial in the New York Times (“Biologics Boondoggle”; 3/8/10). To start, the authors claim that the provisions in the House and Senate health care reform bills would “discourage the development and significantly Read More >

In its 30-year history, biotechnology has made dramatic advances possible in health care, agriculture, energy production and industrial bioprocessing. These accomplishments are the result of painstaking work by many smart people devoted to transforming bench-scale life-science research into commercial products. In economic times both strong and weak this industry thrives. The industry and the promise of its science were tested during the recent and continuing recession. Many biotech companies were forced to downsize or even Read More >

On Sunday, Feb. 28, millions of people around the world will observe “World Rare Disease Day”. This is an annual event sponsored in the U.S. by the National Organization for Rare Disorders (NORD) and in Europe by the European Rare Disease Organisation (EURORDIS). Plans for the day—and the days leading up to it—include awareness events sponsored by patient organizations, a rally organized by pre-medical students at the University of Connecticut, a scientific symposium at the Read More >

The biotechnology industry’s endeavor to transform science into therapy for a previously untreatable disease is the subject of a new movie, “Extraordinary Measures.” The movie is the story of John Crowley, founder of Novazyme, and his struggle to find funding to develop a therapy for Pompe disease. The story, though, may not seem so out of the ordinary to those in the biotechnology industry who conduct vital research and development on products that will help Read More >

BIOtech Now is the first in a number of new products from BIO intended to enhance our communications with the biotech community — not only with our members, but with other stakeholders as well. This monthly e-newsletter, combined with its web site, serves as our flagship in that effort. BIOtech Now will: Offer original content that emphasizes the business needs of the industry. Highlight BIO’s advocacy efforts. Provide a portal to all BIO activities and Read More >